Article Text

Download PDFPDF
Evidence for efficacy of a drug widely used without authorisation in multiple sclerosis: mycophenolate mofetil
  1. Jun-ichi Kira
  1. Correspondence to Professor J-I Kira, Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan; kira{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor that has profound immunosuppressive effects on activated T cells, B cells and macrophages. MMF selectively inhibits inosine 5′-monophosphate dehydrogenase type II, responsible for de novo synthesis of the purine nucleotide guanine. The drug has been used for anti-rejection therapy in organ transplantation and also for immunotherapy in a myriad of autoimmune diseases, including refractory multiple sclerosis (MS). The efficacy of MMF has been examined in several preliminary prospective studies using relatively small numbers of active relapsing–remitting MS patients, in which MMF was introduced as an add on therapy for interferon β.15 These studies mostly showed …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles